The haemodynamic effects of adrenomedullin and calcitonin gene-related peptide (CGRP) were studied in resistance and capacitance vessels of healthy volunteers. Methods Adrenomedullin and CGRP were infused into the brachial artery of eight healthy subjects on two separate occasions at doses between 0.3-30 pmol min −1 .
Introduction peptide, calcitonin gene-related peptide (CGRP) [1] , and it has been suggested that adrenomedullin may act via binding Adrenomedullin is a novel, 52 amino acid vasodilator peptide, originally discovered in human phaeochromocytoma to receptors for CGRP [9] . In the isolated mesenteric vascular bed of the rat, adrenomedullin causes vasodilatation [1] , but which is also present in the plasma of healthy subjects and patients with hypertension [2] . The presence of which can be blocked by the CGRP receptor antagonist, CGRP [10]. Since endogenous CGRP is localised adrenomedullin in normal tissues and plasma [3] , and its synthesis and release by endothelial cells in vitro [4] , suggests to perivascular nerve fibres in the mesenteric vascular bed, this finding could be explained either by adrenomedullin that the peptide has a physiological role in cardiovascular control. In animal studies, adrenomedullin exerts a potent interacting with CGRP receptors and/or by releasing endogenous CGRP. In this context it is notable that, in hypotensive effect [1, 5] which is due to vasodilatation [6] . Bolus injections of adrenomedullin increase blood flow in conscious rats, the regional haemodynamic effects of exogenous adrenomedullin are not influenced by CGRP the renal, mesenteric and hindquarter vascular beds of conscious rats [7] . Recently increased plasma levels of [8-37] [7] . Our objectives in this study were to determine whether adrenomedullin was a vasodilator in the resistance adrenomedullin have been reported in patients with hypertension [2, 8] Blood flow in the control (non-infused) arm did not change significantly throughout the experimental period on any 30 mmHg, was measured using the technique previously described by Aellig [13] . Briefly, 30 min after cannulation, study day, confirming that at the doses infused adrenomedullin and CGRP did not produce systemic effects. a linear variable differential transformer (LVDT) (Lucas, UK) was mounted onto the dorsum of the hand by means Adrenomedullin increased forearm blood flow from 3.4±0.5 ml 100 ml −1 min −1 to 13.0±1.1 ml 100 ml
of a tripod. The LVDT's lightweight core was placed over the summit of the vein being studied, approximately 10 mm min −1 at the highest dose, 30 pmol min −1 (P<0.001) ( Figure 1 ). CGRP, also at a dose of 30 pmol min −1 , downstream from the tip of the infusion cannula. Under the laboratory conditions used, veins have no intrinsic tone [14] , increased forearm blood flow from 3.0±0.2 ml 100 ml
min −1 to 11.4±1.1 ml 100 ml −1 min −1 (P<0.001) therefore, in measuring responses to vasodilators, veins were first preconstricted by 60-70% of maximum with noradrenaline. All drugs were dissolved in saline (140 mm NaCl; Travenol) and infused at a total rate of infusion, maintained constant throughout all studies, of 0.25 ml min −1 .
Protocol 1: Arterial infusion studies and blood flow in forearm resistance vessels
This study was performed in eight subjects (six male, two female; aged 19-28 years) who attended on two separate occasions at least 1 week apart. On the first occasion, following a 30 min period of supine rest, basal values of forearm blood flow were established during a 12 min period of intra-arterial infusion of saline. Adrenomedullin was then infused at doses of 0.3, 1, 3, 10 and 30 pmol min
, with each dose given at 1.0 ml min −1 for 6 min. Saline was then infused for a further 36 min to follow the offset of the effect. On the second occasion, exactly the same protocol was followed except that CGRP was infused at doses of 0.3, 1, 3, 10 and 30 pmol min took part in two separate vein studies, each separated by at (Figure 1 ). The offset of the vasodilatation produced by adrenomedullin and CGRP also differ in conscious sheep. Equimolar doses of adrenomedullin and CGRP produced a both peptides was prolonged, with 50% of the maximum effect still present 18 min after discontinuation of the similar reduction in blood pressure, but adrenomedullin produced a three-fold greater vasodilatation, as assessed by infusion. The percentage increase in forearm blood flow to adrenomedullin was significantly greater than that to CGRP total peripheral conductance [5] . ; P<0.001) (Figure 2) . Despite a decrease in venodilatation at the second dose, between 10 and 30 pmol min −1 , although the duration of effect was similar for the two peptides. The lack of change CGRP reversed constriction by 72±12% at the highest dose (P<0.01) (Figure 2 ). In agreement with its effect in in the control arm provides evidence that the dosedependent vasodilatation occurs in response to a local action the forearm resistance vessels adrenomedullin produced significantly greater venodilatation than CGRP at doses of adrenomedullin or CGRP on the brachial arterial vasculature, rather than via a centrally-mediated mechanism. between 0.3 and 3 pmol min −1 .
The dilator response to adrenomedullin (34±6%) was apparent at a dose of 1 pmol min However, since adrenomedullin can be synthesised by adrenomedullin and CGRP. A recent study demonstrated that adrenomedullin was 10-fold less potent than CGRP in vascular endothelial cells [4] , local tissue levels may be higher than those measured in the circulation. Levels of adrenomedrelaxing isolated rat mesenteric arteries, although the two peptides were equipotent in their vasodilator effects on ullin in pathophysiological conditions such as hypertension are raised in proportion to disease severity [8], and thus hindquarters blood flow [10] . In our own studies in conscious rats, we have demonstrated that the hypotensive and these studies would support the hypothesis that circulating levels of adrenomedullin in heart failure may be in a range tachycardic actions of adrenomedullin are two-fold greater than those of CGRP [7] . Although bolus injections of capable of influencing peripheral vascular resistance, and therefore, adrenomedullin may be of functional importance adrenomedullin produced significant and long lasting increases in renal and mesenteric blood flow, equimolar in such pathophysiological conditions. Adrenomedullin caused significant venodilatation in predoses of CGRP caused reductions in renal and mesenteric flows, and only transient increases in renal and mesenteric constricted human dorsal hand veins. Because superficial hand veins are involved in thermoregulation, venous tone vascular conductances [7] . The haemodynamic profiles of is highly dependent upon ambient temperature. Using the temperature-controlled laboratory conditions of the present study, we were confident of an absence of venous tone by repeated measurements of basal diameter before infusions commenced. Investigating inhibition by dilator agents or the effects of constrictors in resistance vessels can be complicated by the fact that these vessels will always have some degree of tone. Thus, the absence of intrinsic tone in capacitance vessels provides an advantage over arterial studies in this respect [14, 18] , providing a more comprehensive understanding of the pharmacology of agents being studied. CGRP also caused venodilatation which, in agreement with the arterial studies, was less potent than adrenomedullin. This contrasts with a previous study in which CGRP produced no increase in venous diameter at doses of 5 pmol ml −1 min −1 or less [19] . Although, in the present study, we used up to 10 pmol ml these two peptides act at different receptors [7] . However, adrenomedullin in conscious rats. Br J Pharmacol 1995; 114: ongoing work using specific receptor antagonists may 584-591. provide further evidence in this respect. 
